Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

AIMS/INTRODUCTION: Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus. The aim of the present study was to evaluate the safety and efficacy of tofogliflozin add‐on to glucagon‐like peptide‐1 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Terauchi, Yasuo, Fujiwara, Hisataka, Kurihara, Yuji, Suganami, Hideki, Tamura, Masahiro, Senda, Masayuki, Gunji, Ryoji, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825952/
https://www.ncbi.nlm.nih.gov/pubmed/31033218
http://dx.doi.org/10.1111/jdi.13066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825952/
https://www.ncbi.nlm.nih.gov/pubmed/31033218
http://dx.doi.org/10.1111/jdi.13066

Ejemplares similares